Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Multiple Myeloma 23Lymphoma, Non-Hodgkin 19Hodgkin Disease 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Lymphoma 6Myelodysplastic Syndromes 5Neoplasms, Plasma Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 2Sarcoma, Myeloid 1Pancreatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Juvenile 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Children Cancer, Solid Tumor 1

Interventions

Cisplatin 131Cetuximab 80Radiotherapy 76Docetaxel 59Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11130-nm albumin-bound paclitaxel 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × plerixafor × Clear all
NCT04058145 2020-09-07

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Massachusetts General Hospital

Phase 2 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡